Finally, it should be noted that, since hepatocyte injuries in humans may also be caused by TNF/FasL-dependent apoptosis, it follows that anti-TNF Abs and anti-FasL Abs should be considered for therapeutic strategies for some NASH patients. This evidence concerns the gene TNF and metabolic dysfunction-associated steatohepatitis.